ATTN delivers clinical-grade neurocognitive assessments in 30 minutes — insurance-billable results in 24 hours. Attention is all you need.
Getting a diagnosis for ADHD or early dementia shouldn't take longer than treating it.
Even in major metros, neurocognitive testing backlogs stretch 6–12 months. In rural areas, access is functionally nonexistent.
Full neuropsychological batteries cost $2,000–$5,000 out of pocket. Insurance coverage is inconsistent and approval processes are byzantine.
Existing digital tools like CNS Vital Signs and QbTest are expensive and technically cumbersome — patients frequently fail to complete the workflow.
A vertically integrated platform replacing manual testing, scoring, and report writing.
Precision psychometrics powered by adaptive algorithms. Well-established task paradigms (CPT, working memory, processing speed) that adjust in real-time to patient performance.
Browser-based, device-agnostic, zero installation. Patients complete testing from home with built-in validity checks and an interface designed for completion.
Automated scoring with normative comparisons, signal detection metrics (d-prime, response variability), and structured reports that integrate into clinical workflows.
Start with clinician-ordered assessments to build validation and payer relationships, then expand to direct-to-consumer cognitive health monitoring.
A seamless four-stage pipeline designed for both clinical rigor and patient completion.
Clinician selects from a menu of validated cognitive batteries based on the clinical question — ADHD screening, dementia staging, baseline monitoring, or custom panel. Order is placed through our portal or directly via EHR integration.
Patient receives a secure link and completes the assessment in their browser — no downloads, no plugins, no specialized hardware. Built-in environment checks (lighting, audio, device performance) and real-time validity monitoring detect low-effort or distracted performance. Adaptive algorithms adjust task difficulty to maximize diagnostic signal while minimizing fatigue.
Raw performance data is processed through our scoring engine: signal detection theory metrics (d-prime, beta, criterion), ex-Gaussian RT modeling, variability indices, and normative comparisons stratified by age, sex, and education. AI identifies patterns across task domains that human scoring misses — distinguishing true attentional impairment from anxiety, motivation, or environmental confounds.
A structured clinical report is generated and delivered to the ordering clinician — with summary findings, domain-level performance profiles, validity indicators, normative percentiles, and interpretive guidance. Designed to slot directly into a diagnostic workflow, not replace clinical judgment.
Real-world environment. No white-coat effect. Better ecological validity.
Individual cognitive fingerprint for longitudinal tracking against self — not just population norms.
Objective on- vs. off-medication data. Rigorous cognitive endpoints for clinical trials.
Architected for polygenic risk scores, EHR data, and digital phenotyping.
15.5M US adults carry an ADHD diagnosis — a number that has nearly doubled in the past decade, with over half first diagnosed in adulthood. Meanwhile, 7M+ Americans live with Alzheimer's, and cognitive impairment detection is now a required element of Medicare Annual Wellness Visits. Demand for neurocognitive testing vastly outstrips the workforce capacity to deliver it.
ATTN was born from direct clinical frustration. As a physician-scientist treating adults with ADHD at a top academic medical center, I watched patients wait 6–12 months for neurocognitive testing that should take an afternoon. As the parent of a child with ADHD and the son of a mother with early Alzheimer's, the urgency is personal.
This isn't a tech founder guessing at healthcare. This is a tenured clinician-scientist with deep expertise in both the clinical problem and the computational tools to solve it.
We're raising a pre-seed round to launch clinical validation and our first commercial pilots.